Animal models of pancreatic cancer for drug research

Bibliography

• Parker S, Long T, Bolen S, et al. Cancer statistics. CA Cancer J Clin 1997;45:5-27
   Web of Science ®Google Scholar
• Saif MW. Pancreatic cancer: is this bleak landscape finally changing? Highlights from the ‘43rd ASCO Annual Meeting’. Chicago, IL, USA. June 1 – 5, 2007. Jop 2007;8(4):365-73
   PubMedGoogle Scholar
• Lim JE, Chien MW, Earle CC. Prognostoc factors following curative resection for pancreatic adenocarcinomas. Ann Surg 2003;237:74-85
   PubMed Web of Science ®Google Scholar
• Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985 – 1995, using the National Cancer Database. J Am Coll Surg 1999;189:1-7
   PubMed Web of Science ®Google Scholar
• DiMasi JA. The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics 2002;20(Suppl 3):1-10
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007;6(4):1186-97
   PubMed Web of Science ®Google Scholar
• Zalatnai A. Molecular aspects of stromal-parenchymal interactions in malignant neoplasms. Curr Mol Med 2006;6(6):685-93
   PubMed Web of Science ®Google Scholar
• Tepel J, Dagvadorj O, Kapischke M, et al. Significant growth inhibition of orthotopic pancreatic ductal adenocarcinoma by CpG oligonucleotides in immunodeficient mice. Int J Colorectal Dis 2006;21(4):365-72
   PubMed Web of Science ®Google Scholar
• Schabel FM Jr. Animal models as predictive system in cancer chemotherapy fundamental concepts and recent advances year book publishers; 1975
   Google Scholar
• Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 1998;17(3):279-84
   PubMed Web of Science ®Google Scholar
• Pour PM. Experimental pancreatic cancer. Am J Surg Pathol 1989;13:135-55
   Google Scholar
• Hall PA, Lemoine NR. Models of pancreatic cancer. Cancer Surv 1993;16:135-55
   PubMedGoogle Scholar
• Schuh JC. Trials, tribulations, and trends in tumor modeling in mice. Toxicol Pathol 2004;32(Suppl 1):53-66
   PubMedGoogle Scholar
• Grippo PJ, Sandgren EP. Modeling pancreatic cancer in animals to address specific hypotheses. Methods Mol Med 2005;103:217-43
   PubMedGoogle Scholar
• Ruiz-Rabelo JF, Vazquez R, Perea MD, et al. Beneficial properties of melatonin in an experimental model of pancreatic cancer. J Pineal Res 2007;43(3):270-5
   PubMed Web of Science ®Google Scholar
• Chang KW, Laconi S, Mangold KA, et al. Multiple genetic alterations in hamster pancreatic ductal adenocarcinomas. Cancer Res 1995;55(12):2560-8
   PubMed Web of Science ®Google Scholar
• Chang KW, Mangold KA, Hubchak S, et al. Genomic p53 mutation in a chemically induced hamster pancreatic ductal adenocarcinoma. Cancer Res 1994;54(14):3878-83
   PubMed Web of Science ®Google Scholar
• Szepeshazi K, Schally AV, Nagy A, et al. Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog. Pancreas 2005;31(3):275-82
   PubMed Web of Science ®Google Scholar
• Roebuck BD, Longnecker DS. Species and rat strain variation in pancreatic nodule induction by azaserine. J Natl Cancer Inst 1977;59(4):1273-7
   PubMed Web of Science ®Google Scholar
• Corbett TH, Roberts BJ, Leopold WR, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 1984;44(2):717-26
   PubMed Web of Science ®Google Scholar
• Hotz HG, Hines OJ, Foitzik T, et al. Animal models of exocrine pancreatic cancer. Int J Colorectal Dis 2000;15(3):136-43
   PubMed Web of Science ®Google Scholar
• Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer 2007;7(9):645-58
   PubMed Web of Science ®Google Scholar
• Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res 2006;66(1):95-106
   PubMed Web of Science ®Google Scholar
• Longnecker DS. Carcinogenesis in the pancreas. Arch Pathol Lab Med 1983;107(2):54-8
   PubMed Web of Science ®Google Scholar
• Longnecker DS, Curphey TJ, Kuhlmann ET, et al. Inhibition of pancreatic carcinogenesis by retinoids in azaserine-treated rats. Cancer Res 1982;42(1):19-24
   PubMed Web of Science ®Google Scholar
• Weckbecker G, Tolcsvai L, Liu R, et al. Preclinical studies on the anticancer activity of the somatostatin analog octreotide (SMS 201-995). Digestion 1993;54(Suppl 1):98-103
   PubMedGoogle Scholar
• Becher OJ, Holland EC. Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res 2006;66(7):3355-8, discussion 3358-9
   PubMed Web of Science ®Google Scholar
• Glasner S, Memoli V, Longnecker DS. Characterization of the ELSV transgenic mouse model of pancreatic carcinoma. Histologic type of large and small tumors. Am J Pathol 1992;140(5):1237-45
   PubMed Web of Science ®Google Scholar
• Schaeffer BK, Terhune PG, Longnecker DS. Pancreatic carcinomas of acinar and mixed acinar/ductal phenotypes in Ela-1-myc transgenic mice do not contain c-K-ras mutations. Am J Pathol 1994;145(3):696-701
   PubMed Web of Science ®Google Scholar
• Wagner M, Greten FR, Weber CK, et al. A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. Genes Dev 2001;15(3):286-93
   PubMed Web of Science ®Google Scholar
• Schmid RM, Kloppel G, Adler G, et al. Acinar-ductal-carcinoma sequence in transforming growth factor-alpha transgenic mice. Ann NY Acad Sci 1999;880:219-30
   PubMed Web of Science ®Google Scholar
• Ornitz DM, Palmiter RD, Hammer RE, et al. Specific expression of an elastase-human growth hormone fusion gene in pancreatic acinar cells of transgenic mice. Nature 1985;313(6003):600-2
   PubMed Web of Science ®Google Scholar
• Peat N, Gendler SJ, Lalani N, et al. Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. Cancer Res 1992;52(7):1954-60
   PubMed Web of Science ®Google Scholar
• La Rosa S, Rigoli E, Uccella S, et al. Prognostic and biological significance of cytokeratin 19 in pancreatic endocrine tumours. Histopathology 2007;50(5):597-606
   PubMed Web of Science ®Google Scholar
• Tezel E, Nagasaka T, Tezel G, et al. Characterization of scattered neuroendocrine cells in ductal carcinoma of the pancreas. Pancreas 2002;25(2):136-41
   PubMed Web of Science ®Google Scholar
• Brembeck FH, Schreiber FS, Deramaudt TB, et al. The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice. Cancer Res 2003;63(9):2005-9
   PubMed Web of Science ®Google Scholar
• Izeradjene K, Hingorani SR. Targets, trials, and travails in pancreas cancer. J Natl Compr Canc Netw 2007;5(10):1042-53
   PubMedGoogle Scholar
• Feldmann G, Beaty R, Hruban RH, et al. Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg 2007;14:224-32
   PubMedGoogle Scholar
• Macdonald JS, McCoy S, Whitehead RP, et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a southwest oncology group (SWOG 9924) study. Invest New Drugs 2005;23(5):485-7
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004;22(8):1430-8
   PubMed Web of Science ®Google Scholar
• Militello C, Sperti C, Di Prima F, et al. Clinical evaluation and safety of loxiglumide (CCK-A receptor antagonist) in nonresectable pancreatic cancer patients. Italian Pancreatic Cancer Study Group. Pancreas 1997;14(3):222-8
   PubMed Web of Science ®Google Scholar
• Chau I, Cunningham D, Russell C, et al. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer 2006;94(8):1107-15
   PubMed Web of Science ®Google Scholar
• Kalindjian SB, McDonald IM. Strategies for the design of non-peptide CCK2 receptor agonist and antagonist ligand. Curr Top Med Chem 2007;7(12):1195-204
   PubMed Web of Science ®Google Scholar
• Duffy KT, Wickstrom E. Zebrafish tp53 knockdown extends the survival of irradiated zebrafish embryos more effectively than the p53 inhibitor pifithrin-alpha. Cancer Biol Ther 2007;6(5):675-8
   PubMed Web of Science ®Google Scholar
• Bardeesy N, Aguirre AJ, Chu GC, et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 2006;103(15):5947-52
   PubMed Web of Science ®Google Scholar
• Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res 2006;66(7):3351-4
   PubMed Web of Science ®Google Scholar
• Brekken RA, Sullivan MM, Workman G, et al. Expression and characterization of murine hevin (SC1), a member of the SPARC family of matricellular proteins. J Histochem Cytochem 2004;52(6):735-48
   PubMed Web of Science ®Google Scholar
• Sato N, Fukushima N, Maehara N, et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 2003;22(32):5021-30
   PubMed Web of Science ®Google Scholar
• Welch DR. Technical considerations for studying cancer metastasis in vivo. Clin Exp Metastasis 1997;15(3):272-306
   PubMed Web of Science ®Google Scholar
• Wei D, Xiong HQ, Abbruzzese JL, et al. Experimental animal models of pancreatic carcinogenesis and metastasis. Int J Gastrointest Cancer 2003;33(1):43-60
   PubMedGoogle Scholar
• Sipos B, Moser S, Kalthoff H, et al. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 2003;442(5):444-52
   PubMed Web of Science ®Google Scholar
• Farre L, Casanova I, Guerrero S, et al. Heterotopic implantation alters the regulation of apoptosis and the cell cycle and generates a new metastatic site in a human pancreatic tumor xenograft model. FASEB J 2002;16(9):975-82
   PubMed Web of Science ®Google Scholar
• Keyes KA, Mann L, Teicher B, et al. Site-dependent angiogenic cytokine production in human tumor xenografts. Cytokine 2003;21(2):98-104
   PubMed Web of Science ®Google Scholar
• Kouniavsky G, Khaikin M, Zvibel I, et al. Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines. Clin Exp Metastasis 2002;19(1):55-60
   PubMed Web of Science ®Google Scholar
• Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eight G.H.A.Clowes memorial award lecture. Cancer Res 1990;50(19):6130-8
   PubMed Web of Science ®Google Scholar
• Paget S. The distribution of seconday growth in cancer in the breast. Lancet 1889;1:571-3
   Google Scholar
• Arjona AA, Alvarez E. Tumor side implantation and animal model selection in oncology. In: Teicher B, editor, Cancer drug resitance. Humana Press; 2006. p. 151-9
   Google Scholar
• Furukawa T, Kubota T, Watanabe M, et al. A novel “patient-like” treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice. Cancer Res 1993;53(13):3070-2
   PubMed Web of Science ®Google Scholar
• An Z, Wang X, Kubota T, et al. A clinical nude mouse metastatic model for highly malignant human pancreatic cancer. Anticancer Res 1996;16(2):627-31
   PubMed Web of Science ®Google Scholar
• Fu X, Guadagni F, Hoffmann RM. A metastatic nude mouse model of human pancreatic cancer constructed orthotopically from histologically intact patient specimens. Proc Natl Acad Sci USA 1992;89:5645-9
   PubMed Web of Science ®Google Scholar
• Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 1999;17(4):343-59
   PubMed Web of Science ®Google Scholar
• Hotz HG, Reber HA, Hotz B, et al. An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer. Pancreas 2003;26(4):e89-98
   PubMedGoogle Scholar
• Tepel J, Kruse ML, March C, et al. Terminally modified oligodeoxynucleotides directed against p53 in an orthotopic xenograft model: a novel adjuvant treatment strategy for pancreatic ductal carcinoma. Pancreas 2004;28(1):1-12
   PubMed Web of Science ®Google Scholar
• Tepel J, March C, Ketterer T, et al. A modified random oligonucleotide-based combination therapy for adjuvant treatment of pancreatic ductal adenocarcinoma. Int J Oncol 2006;28(5):1105-12
   PubMed Web of Science ®Google Scholar
• Kapischke M, Fischer T, Tiessen K, et al. Characterisation of a novel matrix metalloproteinase inhibitor on pancreatic adenocarcinoma cells in vitro and in an orthotopic pancreatic cancer model in vivo. Int J Oncol 2008;32(1):273-82
   PubMed Web of Science ®Google Scholar
• Fiebig HH, Burger AM. Human tumor xenografts and explants. In: Teicher BA, editor, Animal models in cancer research. Humana Press, Inc.: Totowa; 2001. p. 113-37
   Google Scholar
• Tepel J, Kruse ML, Kapischke M, et al. Adjuvant treatment of pancreatic carcinoma in a clinically adapted mouse resection model. Pancreatology 2006;6(3):240-7
   PubMed Web of Science ®Google Scholar
• Burger AM, Fiebig HH. Screening using animal systems. In: Baguley BC, Kerr DJ, editors. Anticancer drug development. Academic press: San Diego; 2001; p. 285-97
   Google Scholar
• Ishii S, Nagasawa M, Kariya Y, et al. Selective cytotoxic activity of brefeldin A against human tumor cell lines. J Antibiot (Tokyo) 1989;42(12):1877-8
   PubMed Web of Science ®Google Scholar
• Maletzki C, Linnebacher M, Kreikemeyer B, et al. Pancreatic cancer regression by intratumoral injection of live Streptococcus pyogenes in a syngeneic mouse model. Gut 2008;57:483-91
   PubMed Web of Science ®Google Scholar
• Talmadge JE, Singh RK, Fidler IJ, et al. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 2007;170(3):793-804
   PubMed Web of Science ®Google Scholar
• Gong H, Sinz MW, Feng Y, et al. Animal models of xenobiotic receptors in drug metabolism and diseases. Methods Enzymol 2005;400:598-618
   PubMed Web of Science ®Google Scholar
• Argilla D, Chin K, Singh M, et al. Absence of telomerase and shortened telomeres have minimal effects on skin and pancreatic carcinogenesis elicited by viral oncogenes. Cancer Cell 2004;6(4):373-85
   PubMed Web of Science ®Google Scholar
• Caldwell J. The current status of attempts to predict species differences in drug metabolism. Drug Metab Rev 1981;12(2):221-37
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ, Yu AM. Cytochrome P450 and xenobiotic receptor humanized mice. Annu Rev Pharmacol Toxicol 2006;46:41-64
   PubMed Web of Science ®Google Scholar
• Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001;25(5):579-86
   PubMed Web of Science ®Google Scholar
• Vezeridis MP, Tzanakakis GN, Meitner PA, et al. In vivo selection of a highly metastatic cell line from a human pancreatic carcinoma in the nude mice. Cancer 1992;69(8):2060-3
   PubMed Web of Science ®Google Scholar
• Loukopoulos P, Kanetaka K, Takamura M, et al. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas 2004;29(3):193-203
   PubMed Web of Science ®Google Scholar
• Kripke ML, Gruys E, Fidler IJ. Metastatic herterogenity of cells from ultraviolet light-induced murine fibrosarkoma of recent origin. Cancer Res 1978;38:2962-7
   PubMed Web of Science ®Google Scholar
• Kubota T. Metastatic models of human cancer xenografted in the nude mouse: the importance of orthotopic transplantation. J Cell Biochem 1994;56:4-8
   PubMed Web of Science ®Google Scholar
• Xie K, Huang S, Dong Z, et al. Direct correlation between expression of endogenous inducible nitric oxide synthase and regression of M5076 reticulum cell sarcoma hepatic metastases in mice treated with liposomes containing lipopeptide CGP 31362. Cancer Res 1995;55(14):3123-31
   PubMed Web of Science ®Google Scholar
• Khanna C, Hunter K. Modeling metastasis in vivo. Carcinogenesis 2005;26(3):513-23
   PubMed Web of Science ®Google Scholar
• Ciancio SJ, Coburn M, Hornsby PJ. Cutaneous window for in vivo observations of organs and angiogenesis. J Surg Res 2000;92(2):228-32
   PubMed Web of Science ®Google Scholar
• Brown EB, Campbell RB, Tsuzuki Y, et al. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat Med 2001;7(7):864-8
   PubMed Web of Science ®Google Scholar
• Yang M, Baranov E, Li XM, et al. Whole-body and intravital optical imaging of angiogenesis in orthotopically implanted tumors. Proc Natl Acad Sci USA 2001;98(5):2616-21
   PubMed Web of Science ®Google Scholar
• Yang M, Baranov E, Wang JW, et al. Direct external imaging of nascent cancer, tumor progression, angiogenesis, and metastasis on internal organs in the fluorescent orthotopic model. Proc Natl Acad Sci USA 2002;99(6):3824-9
   PubMed Web of Science ®Google Scholar
• Ziske C, Tiemann K, Schmidt T, et al. Real-time high-resolution compound imaging allows percutaneous initiation and surveillance in an orthotopic murine pancreatic cancer model. Pancreas 2008;36(2):146-52
   PubMed Web of Science ®Google Scholar
• Korpanty G, Carbon JG, Grayburn PA, et al. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res 2007;13(1):323-30
   PubMed Web of Science ®Google Scholar
• Ray P, Wu AM, Gambhir SS. Optical bioluminescence and positron emission tomography imaging of a novel fusion reporter gene in tumor xenografts of living mice. Cancer Res 2003;63(6):1160-5
   PubMed Web of Science ®Google Scholar
• Sweeney TJ, Mailander V, Tucker AA, et al. Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci USA 1999;96(21):12044-9
   PubMed Web of Science ®Google Scholar
• Katz MH, Takimoto S, Spivack D, et al. A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics. J Surg Res 2003;113(1):151-60
   PubMed Web of Science ®Google Scholar
• Shankar S, Ganapathy S, Hingorani SR, et al. EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci 2008;13:440-52
   PubMed Web of Science ®Google Scholar
• Keyes KA, Mann L, Cox K, et al. Circulating angiogenic growth factor levels in mice bearing human tumors using luminex multiplex technology. Cancer Chemother Pharmacol 2003;51(4):321-7
   PubMed Web of Science ®Google Scholar
• Bellone G, Novarino A, Chiappino I, et al. Circulating vascular endothelial growth factor and interferon-gamma-inducible protein-10 levels in pancreatic cancer during chemotherapy. Anticancer Res 2005;25(5):3287-91
   PubMed Web of Science ®Google Scholar
• Decker S, Hollingshead M, Bonomi CA, et al. The hollow fibre model in cancer drug screening: the NCI experience. Eur J Cancer 2004;40(6):821-6
   PubMed Web of Science ®Google Scholar
• Suggitt M, Bibby MC. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res 2005;11(3):971-81
   PubMed Web of Science ®Google Scholar
• Hollingshead MG, Alley MC, Camalier RF, et al. In vivo cultivation of tumor cells in hollow fibers. Life Sci 1995;57(2):131-41
   PubMed Web of Science ®Google Scholar
• Shnyder SD, Hasan J, Cooper PA, et al. Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature. Anticancer Res 2005;25(3B):1889-94
   PubMed Web of Science ®Google Scholar
• Yang HW, Kutok JL, Lee NH, et al. Targeted expression of human MYCN selectively causes pancreatic neuroendocrine tumors in transgenic zebrafish. Cancer Res 2004;64(20):7256-62
   PubMed Web of Science ®Google Scholar
• Solorzano CC, Baker CH, Bruns CJ, et al. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm 2001;16(5):359-70
   PubMed Web of Science ®Google Scholar
• Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23(31):8033-40
   PubMed Web of Science ®Google Scholar
• Wei D, Wang L, He Y, et al. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 2004;64(6):2030-8
   PubMed Web of Science ®Google Scholar
• El-Rayes BF, Zalupski MM, Shields AF, et al. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest New Drugs 2005;23(6):583-90
   PubMed Web of Science ®Google Scholar
• Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9(11):4227-39
   PubMed Web of Science ®Google Scholar
• Peterson JK, Houghton PJ. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 2004;40(6):837-44
   PubMed Web of Science ®Google Scholar
• Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000;19(56):6642-50
   PubMed Web of Science ®Google Scholar
• Kerbel RS. What is the optimal rodent model for anti-tumor drug testing? Cancer Metastasis Rev 1999;17(3):301-4
   Web of Science ®Google Scholar